Personalized Medicine Stocks
Precision therapeutics and diagnostic platforms leverage genomic sequencing, molecular profiling, and bioinformatics to shift healthcare from broad population-based treatments to individualized clinical interventions.
As of Oct 23, 2026, Personalized Medicine has 23 US-listed companies worth $40.9B combined. The median member moved +4.5% over the past week; MYGN led at +46.2% and CATX trailed at -25.8%.
Companies in Personalized Medicine
- TEM – Tempus AI, Inc. Class A Common Stock, $12.3B
- HIMS – Hims Hers Health Inc, $6.8B
- BLLN – BillionToOne, Inc. Class A Common Stock, $4.8B
- VCYT – Veracyte Inc, $3.7B
- CDNA – CareDx Inc, $3.6B
- VCEL – Vericel Corp Ord, $2.1B
- PSNL – Personalis Inc, $1.7B
- AZTA – Azenta Inc, $1.5B
- ANRO – Alto Neuroscience, Inc., $956M
- PROK – ProKidney Corp., $695M
- SOPH – Sophia Genetics SA, $687M
- SENS – Senseonics Holdings, Inc. Common Stock, $484M
- MYGN – Myriad Genetics Inc, $396M
- CARL – Carlsmed, Inc., $390M
- PRE – Prenetics Global Ltd, $361M
- CATX – Perspective Therapeutics Inc., $259M
- HURA – TuHURA Biosciences Inc, $117M
- BCTX – Briacell Therapeutics Corp, $30.1M
- ALLR – Allarity Therapeutics Inc, $13.9M
- ADVB – Advanced Biomed Inc. Common Stock, $10.5M
- GENE – Genetic Technologies Ltd, $3.7M
- PRPH – ProPhase Labs Inc, $155,925
- THMO – Thermogenesis Holdings Inc, $1,584